Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tick-borne encephalitis virus (TBEV) is a positive-sense, single-stranded RNA virus belonging to the genus *Flavivirus*. It is the causative agent of tick-borne encephalitis (TBE), a viral infectious disease that primarily affects the central nervous system and can lead to meningitis, encephalitis, or meningoencephalitis. Transmission occurs primarily through tick bites and, less commonly, through consumption of unpasteurized dairy products. Key proteins include the envelope protein (E) which mediates cell entry and induces protective immunity, capsid protein (C) which forms the nucleocapsid, and non-structural proteins (NS3, NS5) involved in replication. There is no specific antiviral treatment; management focuses on supportive care. Vaccination is available for prevention.
N/A (no specific antiviral treatment; vaccines induce neutralizing antibodies)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tick-borne Encephalitis Virus (TBEV).